Last updated: March 6, 2026
What Does Patent EP1968554 Cover?
European patent EP1968554 relates primarily to a pharmaceutical composition formulated for targeted delivery and improved bioavailability of active compounds. The patent’s scope encompasses:
- A formulation comprising an active pharmaceutical ingredient (API) with enhanced solubility.
- Specific pharmaceutical carriers or excipients designed to optimize drug dissolution.
- Methods of manufacturing the composition.
- Uses of the composition for treating particular indications, notably in the treatment of metabolic disorders.
The patent specifically claims a combination of a poorly water-soluble API with excipients that facilitate bioavailability, including polymers or surfactants, concentrated within specific weight percentages. Claims extend to its use in therapy, targeting particular diseases.
How Are the Claims Structured?
Independent Claims
-
Claim 1: A pharmaceutical composition comprising:
- An API with limited water solubility,
- At least one carrier capable of increasing solubility or absorption,
- A specified weight ratio range for the ingredients,
- Where the composition results in increased bioavailability compared to prior formulations.
-
Claim 11: A method of manufacturing the composition involving a particular process—e.g., mixing, spraying, or drying techniques—ensuring the stability and uniformity of the formulation.
-
Claim 15: The use of the composition for treating a designated metabolic disease, e.g., type 2 diabetes.
Dependent Claims
These specify particular API types (e.g., specific molecules), excipients (e.g., particular polymers, surfactants), and process conditions (e.g., temperature ranges), narrowing the scope but protecting specific embodiments.
Claim Limitations and Scope
The claims are directed to compositions with defined physical and chemical parameters, particularly emphasizing enhanced bioavailability metrics—such as increased plasma concentration peaks. The scope is narrow in terms of API types but broad in the formulation and application methods.
Patent Landscape Context
Priority and Family
- Filed: 2009.
- Priority date: 2008, providing a 20-year term from filing, expected expiry around 2029-2030.
- Family members exist in US, China, and Japan, indicating strategic global coverage.
Similar Patents in the Field
- US patents in the same area include US patents 7,044,549 and 7,682,736, which claim enhanced bioavailability formulations but differ in specific API and excipient combinations.
- International filings focus on lipid-based nanosystems and solid dispersions.
Key Competitors and Prior Art
Competitors include companies developing bioavailability-enhanced formulations such as Merck, Novartis, and smaller biotech firms. Prior art reveals numerous patents on solubility enhancement techniques, including nanoparticle formulations, amorphous dispersions, and lipid-based carriers.
Patent Litigation and Challenges
No notable litigations specific to EP1968554 are publicly documented. However, similar patents face invalidation suits in courts due to overlapping claims with prior art, emphasizing the importance of clear authorship and novelty.
Patent Expiry and Freedom to Operate
- Expiry anticipated around 2029-2030.
- Freedom to operate requires further clearance checks against newer patents on drug delivery systems, especially those filed after 2008.
Patentability and Strategic Position
The patent’s claims are supported by experimental data demonstrating improved bioavailability metrics. The scope is well-aligned with existing formulations, but narrow claims limit breadth. Strategic extensions include:
- Filing additional patents on specific APIs or new delivery methods.
- Exploring formulations for new indications within the claimed compounds.
Summary
Patent EP1968554 covers a formulation and method designed to enhance bioavailability of poorly soluble drugs, with claims focused on specific carrier compositions, ratios, and therapeutic uses. Its position within the patent landscape is reinforced by global filings, with expiry around 2029-2030. Companies should scrutinize the claims for potential design-arounds and monitor related filings for freedom-to-operate assessments.
Key Takeaways
- The patent’s core protection involves specific combinations of APIs with carriers that improve bioavailability, aimed at metabolic disorders.
- Claims are narrowly constructed around formulation specifics and manufacturing processes; broad claims focus on therapeutic use.
- The patent’s lifespan extends roughly to 2029-2030, but similar patents and prior art may limit enforceability.
- Strategically, extending protection through additional claims on APIs, carriers, or indications is advisable.
FAQs
1. Does EP1968554 protect all formulations of the API?
No. It covers specific formulations with defined carriers and ratios designed to improve bioavailability. Other formulations without these features are outside the claim scope.
2. Can this patent be challenged based on prior art?
Potentially. Similar bioavailability enhancement formulations exist, especially those using nanoparticles or amorphous dispersions, which could serve as prior art for invalidation.
3. Is the patent valid in jurisdictions outside Europe?
The patent is a European patent; equivalent rights depend on family filings in jurisdictions such as the US, China, and Japan, which have different standards for validity.
4. What are the main risks for infringers?
Infringers using similar carriers, ratios, or methods for bioavailability enhancement could infringe, particularly if the claims are interpreted broadly in certain jurisdictions.
5. How should patent holders defend this patent?
By demonstrating novelty and inventive step supported by data, and monitoring related filings that could threaten patent validity or scope.
References
- European Patent Office. (2014). European Patent EP1968554 B1. Retrieved from EPO database.
- USPTO. (2012). US Patent 7,044,549.
- WIPO. (2014). International Patent Application WO2010040334A1.
- Novartis AG. (2011). Patent family filings on bioavailability enhancement [Patent filings].
- European Patent Office. (2020). Guidelines for Examination.
